Chemotherapy-induced cardiotoxicity and mitigation
Chemotherapy-induced cardiotoxicity and mitigation is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 14k research works in it since 1956. 10.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.
- Anthracyclines
- Doxorubicin
- Cardiomyopathy
- Chemotherapy
- Cardiovascular Complications
- Trastuzumab
- Oxidative Stress
- Cardiac Dysfunction
- Prevention
- Survivors
- Research works
- 14k fractional, since 1956
- In the world top 10%
- 1.4k per year above
- Top-10% rate
- 10.1% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +35% the tick is no change
- Largest producer
United States
38% of the 10 largest, 2022-now
Drawing this view